Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092879 | 0.89 | LOXL2 (0.49) | LOXL2CHRM2MC4RMMP2IDO1 | |
| SCHEMBL6523856 | 0.89 | LOXL2 (0.49) | LOXL2CHRM2MC4RMMP2IDO1 | |
| SCHEMBL4104161 | 0.89 | LOXL2 (0.49) | LOXL2CHRM2MC4RMMP2IDO1 | |
| Hydrochloric Acid SCHEMBL2511527 | 0.88 | LOXL2 (0.47) | LOXL2CHRM2MC4RMMP2IDO1 | |
| Hydrochloric Acid SCHEMBL2511528 | 0.88 | LOXL2 (0.47) | LOXL2CHRM2MC4RMMP2IDO1 | |
| SCHEMBL8829958 | 0.88 | LOXL2 (0.50) | LOXL2CHRM2MC4RMMP2IDO1 | |
| SCHEMBL28541344 | 0.85 | LOXL2 (0.47) | LOXL2CHRM2MC4RMMP2IDO1 | |
| SCHEMBL12793699 | 0.84 | CHRM2 (0.49) | LOXL2CHRM2MC4RMMP2IDO1 | |
| SCHEMBL8829959 | 0.82 | LOXL2 (0.47) | LOXL2CHRM2MC4RMMP2IDO1 | |
| SCHEMBL5099679 | 0.80 | LOXL2 (0.47) | LOXL2CHRM2MC4RMMP2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143229-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-11260136-B2 | Radio-pharmaceutical complexes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-03-01 | — | — | US | disclosed |
| US-20210322583-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2021-10-21 | — | — | US | disclosed |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-03 | — | — | US | disclosed |
| EP-3468619-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer Pharma Aktiengesellschaft (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20190091354-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-28 | — | — | US | disclosed |
| EP-3432936-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017211809-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-14 | — | — | WO | disclosed |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2017-11-30 | — | — | US | disclosed |
| EP-3233137-A1 | RADIO-PHARMACEUTICAL COMPLEXES | Bayer AS (NO) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017162555-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016096843-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322583-A1 | RADIO-PHARMACEUTICAL COMPLEXES | PTMS, THOP1, PHPT1 | LOXL2 2044/4885CHRM2 554/4885MC4R 3090/4885 |
| US-20220143229-A1 | RADIO-PHARMACEUTICAL COMPLEXES | EGFR, MET, ERBB2 | LOXL2 1316/4885CHRM2 863/4885MC4R 2818/4885 |
| US-11260136-B2 | Radio-pharmaceutical complexes | EGFR, MET, ERBB2 | LOXL2 1442/4885CHRM2 645/4885MC4R 2860/4885 |
| US-20170340759-A1 | RADIO-PHARMACEUTICAL COMPLEXES | PTMS, THOP1, PHPT1 | LOXL2 1992/4885CHRM2 553/4885MC4R 3064/4885 |
| US-20190091354-A1 | RADIO-PHARMACEUTICAL COMPLEXES | EGFR, MET, ERBB2 | LOXL2 1388/4885CHRM2 706/4885MC4R 2908/4885 |
| US-20190298865-A1 | RADIO-PHARMACEUTICAL COMPLEXES | FAP, PHPT1, DNPEP | LOXL2 659/4885CHRM2 3124/4885MC4R 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.